VBI Vaccines Inc. announced that the UK Medicines and Healthcare Products Regulatory Agency (MHRA) has granted marketing authorization for PreHevbri [Hepatitis B vaccine (recombinant, adsorbed)] for active immunization against infection caused by all known subtypes of the hepatitis B virus (HBV) in adults. It can be expected that hepatitis D will also be prevented by immunization with PreHevbri as hepatitis D (caused by the delta agent) does not occur in the absence of hepatitis B infection.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.5994 USD | +1.59% | -4.81% | +2.03% |
Apr. 16 | VBI Vaccines Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Apr. 15 | North American Morning Briefing : Stock Futures -2- | DJ |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+2.03% | 17.04M | |
+1.12% | 42.59B | |
+6.77% | 40.65B | |
+45.26% | 40.57B | |
-11.96% | 26.77B | |
+6.01% | 24.81B | |
-24.92% | 18.17B | |
-3.63% | 11.7B | |
+27.16% | 12.05B | |
+7.30% | 11.1B |
- Stock Market
- Equities
- VBIV Stock
- News VBI Vaccines Inc.
- VBI Vaccines Inc. Announces UK MHRA Marketing Authorisation for Prehevbri